Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 13 |
Bispecific antibody | 6 |
Small molecule drug | 3 |
Biological products | 1 |
Antibody fusion proteins | 1 |
Target |
Mechanism PD-1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date21 May 2024 |
Target |
Mechanism PD-1 inhibitors |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date19 Jul 2022 |
Target |
Mechanism CTLA4 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date28 Jun 2022 |
Start Date15 Jul 2024 |
Sponsor / Collaborator Wuhan Union Hospital [+1] |
Start Date02 Jul 2024 |
Sponsor / Collaborator |
Start Date20 Jun 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Ivonescimab ( PD-1 x VEGF-A ) | EGFR positive Non-squamous non-small cell lung cancer More | Approved |
Gumokimab ( IL-17 ) | Ankylosing Spondylitis More | Phase 3 |
Quavonlimab ( CTLA4 ) | Renal Cell Carcinoma More | Phase 3 |
Cadonilimab ( CTLA4 x PD-1 ) | Recurrent Cervical Cancer More | Phase 2 |
Ligufalimab ( CD47 ) | High Risk Myelodysplastic Syndrome More | Phase 2 |